Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond

Abstract

Pancreatic enzymes assist metabolic digestion, and hormones like insulin and glucagon play a critical role in maintaining our blood sugar levels. A malignant pancreas is incapable of doing its regular functions, which results in a health catastrophe. To date, there is no effective biomarker to detect early-stage pancreatic cancer, which makes pancreatic cancer the cancer with the highest mortality rate of all cancer types. Primarily, mutations of the KRAS, CDKN2A, TP53, and SMAD4 genes are responsible for pancreatic cancer, of which mutations of the KRAS gene are present in more than 80% of pancreatic cancer cases. Accordingly, there is a desperate need to develop effective inhibitors of the proteins that are responsible for the proliferation, propagation, regulation, invasion, angiogenesis, and metastasis of pancreatic cancer. This article discusses the effectiveness and mode of action at the molecular level of a wide range of small molecule inhibitors that include pharmaceutically privileged molecules, compounds under clinical trials, and commercial drugs. Both natural and synthetic small molecule inhibitors have been counted. Anti-pancreatic cancer activity and related benefits of using single and combined therapy have been discussed separately. This article sheds light on the scenario, constraints, and future aspects of various small molecule inhibitors for treating pancreatic cancer—the most dreadful cancer so far.

Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer

“…These include efforts to modulate the tumor microenvironment so that checkpoint inhibitors may ultimately prove effective as well as developing cellular therapies to directly target pancreatic cancers [ 27 ]. Other significant efforts continue to expand our understanding of the molecular subtypes of pancreatic cancers, and to advance our potential ability to take advantage of these findings with the development of agents that can target the key alterations in these subtypes [ 28 ]. For example, targeting KRAS alterations is an area of extensive study in the current field [ 29 ].…”

Navigating breast cancer complexity: Deciphering the cross talk of Wnt/β catenin and Notch pathways in development and diseases

“…These GSIs have been initially explored as a potential ministration for Dementia due to their ability to inhibit -secretase from producing -amyloid peptide. However, clinical trials for AD (Alzheimer's disease) were terminated early due to severe side effects of NOTCH, such as infections, digestive issues, and nonmelanoma skin malignancies 161 . Subsequently, GSIs gained attention as a potential cancer treatment by disrupting NOTCH signalling, showing promising antitumor activity in preclinical studies across various cancerous tumour kinds such as brain tumours, carcinomas of the lungs, cancer of the colon, prostate cancer, and carcinoma of the liver.…”

Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action

“…These include molar refractivity, polar surface area, rotatable bonds, etc. Some commonly used small-molecule drugs are aspirin, atenolol, diazepam, diclofenac, ibuprofen, felodipine, omeprazole, phenytoin, and many others [ 22 , 23 , 24 , 25 ]. This review will shed light on the molecular characterization of TNBC, single drug targets, drug combinations, and different small molecules that are targeted to cause regulated or programmed cell death for the treatment of TNBC.…”